Mechanisms of HCV survival in the host

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 4, 2009, Pages 217-227

  Sklan, Ella H ^a   Charuworn, Prista ^b   Pang, Philip S ^b   Glenn, Jeffrey S ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; INTERFERON; RETINOIC ACID INDUCIBLE PROTEIN I; SCAVENGER RECEPTOR BI; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; DENDRITIC CELL; ETHNICITY; GENETIC POLYMORPHISM; HEPATITIS C VIRUS; HOST; HUMAN; HUMORAL IMMUNITY; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SEX; SIGNAL TRANSDUCTION; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS DETECTION; VIRUS ENTRY; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SHEDDING; VIRUS SURVIVAL; VIRUS TRANSCRIPTION; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; HEPACIVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; VIRUS REPLICATION;

EID: 67649889126     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.32     Document Type: Review

References (105)

1. The Global Burden of Hepatitis C Working Group. Global Burden of Disease (GBD) for Hepatitis C. J. Clin. Pharmacol. 44, 20-29 (2004).
2. Shepard, C. W. et al. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558-567 (2005).
3. Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938-941 (1998).
4. Scarselli, E. et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017-5025 (2002).
5. Acton, S. et al. Identification of scavenger receptor SR-BI as a high-density lipoprotein receptor. Science 271, 518-520 (1996).
6. Connelly, M. A. & Williams, D. L. Scavenger receptor BI: A scavenger receptor with a mission to transport high density lipoprotein lipids. Curr. Opin. Lipidol. 15, 287-295 (2004).
7. Lavie, M. et al. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology 44, 1626-1634 (2006).
8. Von Hahn, T. et al. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 43, 932-942 (2006).
9. Bartosch, B. et al. An interplay between hypervariable region I of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of Infection and protection against neutralizing antibodies. J. Virol. 79, 8217-8229 (2005).
10. Voisset, C. et al. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J. Biol. Chem. 280, 7793-7799 (2005).
11. Murao, K. et al. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes. Gut 57, 664-671 (2008).
12. Bartosch, B. et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278, 41624-41630 (2003).
13. Hsu, M. et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100, 7271-7276 (2003).
14. Evans, M. J. et al. Claudin-1 is a hepatitis C virus coreceptor required for a late step in entry. Nature 446, 801-805 (2007).
15. Ploss, A. et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882-886 (2009).
16. Lozach, P. et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278, 20358-20366 (2003).
17. Cormier, E. G. et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl Acad. Sci. USA 101, 14067-14072 (2004).
18. Weiner, A. J. et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180, 842-848 (1991).
19. Forns, X. et al. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc. Natl Acad. Sci. USA 97, 13318-13323 (2000).
20. Roccasecca, R. et al. Binding of the hepatitis C virus E2 glycoprotein to CD81 Is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J. Virol. 77 1856-1867 (2003).
21. Hofmann, W. P. et al. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: Correlation with treatment response in hepatitis C virus-infected patients. J. Infect. Dis. 187, 982-987 (2003).
22. Jackson, R. J. & Kaminski, A. Internal initiation of translation in eukaryotes: The picomavirus paradigm and beyond. RNA 1, 985-1000 (1995).
23. Kaufman, R. J. Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: A new role for an old actor. Proc. Natl Acad. Sci. USA 96, 11693-11695 (1999).
24. Moradpour, D. et al. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277, 593-601 (2002).
25. Miyanari, Y. et al. Hepatitis C virus nonstructural proteins in the probable membranous compartment function in viral genome replication. J. Biol. Chem. 278, 50301-50308 (2003).
26. Chu, P. W. & Westaway, E. G. Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. Virology 140, 68-79 (1985).
27. Chang, M. et al. Dynamics of hepatitis C virus replication in human liver. Am. J. Pathol. 163, 433-444 (2003).
28. Quinkert, D. et al. Quantitative analysis of the hepatitis C virus replication complex. J. Virol. 79, 13594-13605 (2005).
29. Targett-Adams, P. et al. Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication. J. Virol. 82, 2182-2195 (2008).
30. Martell, M. et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J. Virol. 66, 3225-3229 (1992).
31. Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623-626 (2005).
32. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-796 (2005).
33. Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294-9299 (2005).
34. Gastaminza, P. et al. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 82 2120-2129 (2008).
35. Konan, K. V. et al. Nonstructural protein precursor NS4A/B from hepatitis C virus alters function and ultrastructure of host secretory apparatus. J. Virol. 77, 7843-7855 (2003).
36. Sklan, E. H. et al. TBCID20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication. J. Biol. Chem. 282 36354-36361 (2007).
37. Sklan, E. H. et al. A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication. J. Virol. 81, 11096-11105 (2007).
38. Hobert, O. Gene regulation by transcription factors and microRNAs. Science 319, 1785-1786 (2008).
39. Pedersen, I. M. et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449, 919-922 (2007).
40. Jopling, C. L. et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577-1581 (2005).
41. Sarasin-Filipowicz, M. et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15, 31-33 (2009).
42. Cullen, B. R. Is RNA interference involved in intrinsic antiviral immunity in mammals? Nat. Immunol. 7, 563-567 (2006).
43. Randall, G. et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl Acad. Sci. USA 104, 12884-12889 (2007).
44. Wohnsland, A. et al. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol Rev. 20, 23-38 (2007).
45. Gale, M. Jr & Foy, E. M. Evasion of intracellular host defence by hepatitis C virus. Nature 436, 939-945 (2005).
46. Moradpour, D. et al. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5, 453-463 (2007).
47. Miyamoto, M. et al. Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1). Intervirology 49, 37-43 (2006).
48. Meylan, E. et al. Intracellular pattern recognition receptors in the host response. Nature 442, 39-44 (2006).
49. Foy, E. et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl Acad. Sci. USA 102, 2986-2991 (2005).
50. Li, X.-D. et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl Acad. Sci. USA 102, 17717-17722 (2005).
51. Loo, Y. M. et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc. Natl Acad. Sci. USA 103, 6001-6006 (2006).
52. Li, K. et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA 102, 2992-2997 (2005).
53. Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis, C. Proc. Natl Acad. Sci. USA 105 7034-7039 (2008).
54. Lanford, R. E. et al. Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology 46, 999-1008 (2007).
55. Bigger, C. B. et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J. Virol. 78, 13779-13792 (2004).
56. Janssens, V. & Goris, J. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353, 417-439 (2001).
57. Duong, F. H. et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126, 263-277 (2004).
58. Christen, V. et al. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 46, 558-565 (2007).
59. Taylor, D. R. et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107 (1999).
60. Gale, M. J. Jr et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217-227 (1997).
61. Noguchi, T. et al. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol Immunol. 45, 829-840 (2001).
62. Enomoto, N. et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334, 77-81 (1996).
63. Szabo, G. et al. Altered innate immunity in chronic hepatitis C infection: Cause or effect? Hepatology 46, 1279-1290 (2007).
64. Dolganiuc, A. et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 177 6758-6768 (2006).
65. Jeffers, L. J. et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39, 1702-1708 (2004).
66. He, X. S. et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44, 352-359 (2006).
67. Lanford, R. E. et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J. Virol. 77, 1092-1104 (2003).
68. Hayashi, J. et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch. Intern. Med. 158, 177-181 (1998).
69. Bakr, I. et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut 55, 1183-1187 (2006).
70. Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003).
71. Thursz, M. et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 354, 2119-2124 (1999).
72. Houldsworth, A. et al. Polymorphisms in the IL-12B gene and outcome of HCV infection. J. Interferon Cytokine Res. 25, 271-276 (2005).
73. Khakoo, S. I. et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305, 872-874 (2004).
74. Gao, B. et al. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 39, 880-890 (2004).
75. Farci, P. et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258, 135-140 (1992).
76. Longman, R. S. et al. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 103 1026-1029 (2004).
77. Piccioli, D. et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J. Hepatol. 42, 61-67 (2005).
78. Tsubouchi, E. et al. Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection. J. Gastroenterol. 39, 754-762 (2004).
79. + T-cell proliferation in patients with hepatitis C virus infection. Immunology 121, 283-292 (2007).
80. Dolganiuc, A. et al. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology 135, 2119-2127 (2008).
81. Owsianka, A. M. et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89, 653-659 (2008).
82. Helle, F. et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81, 8101-8111 (2007).
83. Thimme, R. et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl Acad. Sci. USA 99, 15661-15668 (2002).
84. Grakoui, A. et al. HCV persistence and immune evasion in the absence of memory T-cell help. Science 302, 659-662 (2003).
85. + T cells via suppression of dendritic cell IL-12 production. J. Leukoc. Biol. 82, 1407-1419 (2007).
86. Wang, H. & Eckels, D. D. Mutations in immunodominant T-cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T-cell recognition. J. Immunol. 162, 4177-4183 (1999).
87. H2 response. Hum. Immunol. 64, 662-673 (2003).
88. + T cells in chronic hepatitis C virus infection. J. Immunol. 169, 3447-3458 (2002).
89. + T cells. J. Immunol. 172, 1744-1753 (2004).
90. Penna, A. et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45, 588-601 (2007).
91. + T-cell failure during chronic hepatitis C virus infection. Hepatology 42, 828-837 (2005).
92. + T-cell failure in chronic hepatitis C virus infection. Hepatology 47, 1824-1836 (2008).
93. Seifert, U. et al. Hepatitis C virus mutation affects proteasomal epitope processing. J. Clin. Invest. 114, 250-259 (2004).
94. Jeong, H.-Y. et al. Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. J. Leukoc. Biol. 83, 755-764 (2008).
95. Kaplan, M. et al. Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J. Hepatol. 48, 903-913 (2008).
96. + regulatory T cells in hepatitis C virus infection. J. Virol. 82, 5043-5053 (2008).
97. Roque-Afonso, A.-M. et al. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J. Virol. 79, 6349-6357 (2005).
98. Zehender, G. et al. Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. J. Virol. 79, 9145-9156 (2005).
99. Sung, V. M. et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: The apoptotic effects of virus infection. J. Virol. 77, 2134-2146 (2003).
100. Han, J. Q. & Barton, D. J. Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8, 512-525 (2002).
101. Sumpter, R. J. et al. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell-culture model. J. Virol. 78, 11591-11604 (2004).
102. Bode, J. G. et al. IFN-alpha; antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 17, 488-490 (2003).
103. Pflugheber, J. et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc. Natl Acad. Sci. USA 99, 4650-4655 (2002).
104. Polyak, S. J. et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75, 6095-6106 (2001).
105. Polyak, S. J. et al. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 75, 6209-6211 (2001).